Related references
Note: Only part of the references are listed.Animal models of catheter-induced intimal hyperplasia in type 1 and type 2 diabetes and the effects of pharmacologic intervention
D. B. McNamara et al.
CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY (2009)
Specific association between the methyl-CpG-binding domain protein 2 and the hypermethylated region of the human telomerase reverse transcriptase promoter in cancer cells
Amandine Chatagnon et al.
CARCINOGENESIS (2009)
Evaluation of Insulin Resistance in Normoglycemic Patients with Coronary Artery Disease
Erda Deveci et al.
CLINICAL CARDIOLOGY (2009)
The Extrapancreatic Effects of Glucagon-Like Peptide-1 and Related Peptides
Rania Abu-Hamdah et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Exenatide Reduces Infarct Size and Improves Cardiac Function in a Porcine Model of Ischemia and Reperfusion Injury
Leo Timmers et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
Glycemic Targets for Patients with Type 2 Diabetes Mellitus
Ole-Petter R. Hamnvik et al.
MOUNT SINAI JOURNAL OF MEDICINE (2009)
Incretin-based therapies for type 2 diabetes mellitus
Julie A. Lovshin et al.
NATURE REVIEWS ENDOCRINOLOGY (2009)
Exenatide Improves Hypertension in a Rat Model of the Metabolic Syndrome
Kevin D. Laugero et al.
METABOLIC SYNDROME AND RELATED DISORDERS (2009)
Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways
Kiwon Ban et al.
CIRCULATION (2008)
Exenatide as a Treatment for Diabetes and Obesity: Implications for Cardiovascular Risk Reduction
Derek D. Mafong et al.
CURRENT ATHEROSCLEROSIS REPORTS (2008)
Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes
Nasser Mikhail
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2008)
Cardiometabolic risk: a Framingham perspective
P. W. F. Wilson et al.
INTERNATIONAL JOURNAL OF OBESITY (2008)
Incretin-based therapies in type 2 diabetes mellitus
Chee W. Chia et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart
David P. Sonne et al.
REGULATORY PEPTIDES (2008)
The role of gut hormones in glucose homeostasis
Daniel J. Drucker
JOURNAL OF CLINICAL INVESTIGATION (2007)
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
Daniel J. Drucker et al.
LANCET (2006)
Rosiglitazone reduces serum homocysteine levels, smooth muscle proliferation, and intimal hyperplasia in Sprague-Dawley rats fed a high methionine diet
SN Murthy et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2005)
Identification of novel molecular candidates for fatty liver in the hyperlipidemic mouse model, HcB19
MMJ van Greevenbroek et al.
JOURNAL OF LIPID RESEARCH (2004)
Insulin and insulin resistance: impact on blood pressure and cardiovascular disease
JR Sowers et al.
MEDICAL CLINICS OF NORTH AMERICA (2004)
Neointimal hyperplasia after arterial injury is increased in a rat model of non-insulin-dependent diabetes mellitus
SH Park et al.
CIRCULATION (2001)
Share Paper
